Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme known as a free radical scavenging system [1] . PON-1 has three main activities, responsible for its antioxidant and anti-inflammatory potential: paraoxonase, arylesterase and lactonase (LACase), the latest to be discovered and pointed out to be its native activity [2] . Among other physiological roles, the LACase might minimize the deleterious effects of hyperhomocysteinaemia in infection, by detoxifying the highly reactive metabolite homocysteine-thiolactone (HcyTL) [3] , [4] . In the present work, we have developed and applied a method to quantify LACase activity and to explore the role of this enzyme in HIV-infection and virological response. The LACase activity was monitored in a cohort of HIV-1-infected patients, through the titration of 3-(o-hydroxyphenyl) propionic acid, formed upon the LACase-mediated hydrolysis of the substrate dihydrocoumarin. The study protocol was approved by the Ethics Committee of Centro Hospitalar de Lisboa Central and Hospital Prof. Doutor Fernando Fonseca. All patients gave their written informed consent and were adults with documented HIV-1-infection, regardless of combined antiretroviral therapy (cART) use. Naïve patients and patients who had received continuous antiretroviral treatment for more than one month were included. A total of 179 HIV-1-infected patients were included on this study (51% Men, 39% non-Caucasian, 45913 years old). Patients with nonsuppressed viraemia, either from the non-cART (n089, 1294 kU/L, pB0.01) or from the cART with detectable viral load (n 011, 1095 kU/L, pB0.05) groups, had lower activity than the cART with suppressed viraemia (n 079, 1597 kU/L) (KruskalÁ Wallis test). Among naïve patients, higher viral load ( 31,500 cps/mL, Spearman r0(0.535, p 00.003) and lower CD4' Tcells count ( B 500 cell/mm 3 , Pearson r00.326, p00.024) were associated with the LACase activity. The present study suggests that lower LACase activity is associated with uncontrolled HIV-1-infection, particularly with non-suppressed viraemia, despite of cART. This data seems to point to LACase role in HIV-infection, probably reflecting an increased formation of HcyTL deleterious species. A better knowledge of the LACase and its role in HcyTL pathophysiology might identify new therapeutic targets in HIV-1-infected patients. Acknowledgements: EXPL/DTP-FTO/0204/2012; EXPL/DTP-PIC/1758/2013.
